Literature DB >> 30266108

Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.

Jie-Ming Ni1, An-Ping Ni2.   

Abstract

Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) is a significant immune checkpoint, and the dysfunction of this axis contributes to tumor metastasis and immune escape. PI3K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor progression. Transcriptional factors such as hypoxia induced factors, PTEN, p53, CDK5, BRD4, STAT modulate PD-1/PD-L1 expression. PD-1/PD-L1 level is also regulated via epigenetic and post-translational manner. The underlying mechanisms mentioned above may provide potential targets for tumor treatment. At present, the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266108     DOI: 10.24920/21804

Source DB:  PubMed          Journal:  Chin Med Sci J        ISSN: 1001-9294


  10 in total

1.  Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.

Authors:  Dengdeng Pan; Dongliang Liu; Lichuan Liang; Tongyi Shen; Chenzhang Shi; Huanlong Qin
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

2.  Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.

Authors:  Wentao Kuai; Xinjian Xu; Jing Yan; Wujie Zhao; Yaxing Li; Bin Wang; Na Yuan; Zhongxin Li; Yitao Jia
Journal:  Biomed Res Int       Date:  2020-05-14       Impact factor: 3.411

3.  Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma.

Authors:  Tomotaka Ugai; Melissa Zhao; Takashi Shimizu; Naohiko Akimoto; Shanshan Shi; Yasutoshi Takashima; Rong Zhong; Mai Chan Lau; Koichiro Haruki; Kota Arima; Kenji Fujiyoshi; Benjamin Langworthy; Yohei Masugi; Annacarolina da Silva; Katsuhiko Nosho; Yoshifumi Baba; Mingyang Song; Andrew T Chan; Molin Wang; Jeffrey A Meyerhardt; Marios Giannakis; Juha P Väyrynen; Jonathan A Nowak; Shuji Ogino
Journal:  Oncoimmunology       Date:  2021-08-02       Impact factor: 8.110

4.  8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma.

Authors:  Congbo Cai; Lei Yang; Kena Zhou
Journal:  BMC Gastroenterol       Date:  2021-12-12       Impact factor: 3.067

Review 5.  Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.

Authors:  Somayeh Vafaei; Angelina O Zekiy; Ramadhan Ado Khanamir; Burhan Abdullah Zaman; Arman Ghayourvahdat; Hannaneh Azimizonuzi; Majid Zamani
Journal:  Cancer Cell Int       Date:  2022-01-03       Impact factor: 5.722

Review 6.  Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy.

Authors:  Changxian Shen; Yuqi He; Qiang Chen; Haihua Feng; Terence M Williams; Yuanzhi Lu; Zhengfu He
Journal:  Ann Transl Med       Date:  2021-10

7.  Thyroid dysfunction during PD-1 inhibitor treatment in patients with cancer: Incidence and association with progression-free survival.

Authors:  Yanfei Wu; Zhi Wang; Hongxia Bai; Yan Gao
Journal:  Oncol Lett       Date:  2022-07-13       Impact factor: 3.111

Review 8.  Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.

Authors:  Guofeng Ma; Zhilei Zhang; Peng Li; Zhao Zhang; Manqin Zeng; Zhijuan Liang; Dan Li; Liping Wang; Yuanbin Chen; Ye Liang; Haitao Niu
Journal:  Cell Commun Signal       Date:  2022-07-27       Impact factor: 7.525

Review 9.  Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion.

Authors:  Xuejun Shao; Shenghao Hua; Tao Feng; Dickson Kofi Wiredu Ocansey; Lei Yin
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

10.  ADORA1 is a diagnostic-related biomarker and correlated with immune infiltrates in papillary thyroid carcinoma.

Authors:  Xu Lin; Zhi-Yong Wang; Gang Xue; Xiao-Jing Qin; Jing-Fang Wu; Geng Zhang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.